Table 1.

Studies presenting a therapeutic approach to hyperimmune sera in the treatment of coronavirus from 2004 to 2020.

AUTHORS	ARTICLE PROPOSAL
PEIRIS et al., 2004 [94]	Review available information on coronavirus, and its therapies.
SUBBARAO et al., 2004 [95]	Check of the efficiency of passive antibody immunization in the treatment of SARS-CoV.
LU et al., 2005 [93]	Development of an equine hyperimmune serum as a future SARS treatment measure.
WANG et al., 2005 [96]	Evaluation of the protective effects of equine serum F (ab′) 2 against SARS-CoV infection.
XU et al., 2007 [39]	Check of the safety, immunogenicity, and pharmacokinetics of equine anti-SARS serum - CoV F (ab′) 2 in monkeys.
ZHOU et al., 2007 [97]	Evaluation of the preventive, and therapeutic role of anti-SARS-CoV equine serum F (ab′) 2 in elderly mice.
LUO et al., 2007 [98]	Establishment of a new animal model for the study of SARS-CoV in Chinese hamster, and evaluation of the therapeutic action of equine anti-SARS serum in this animal model.
NEWCOMBE & NEWCOMB, 2007 [99]	Examination of contemporary techniques, and applications of polyclonal antibodies, and evaluation of their future therapeutic potential.
ZHAO et al., 2015 [100]	Investigation of the prophylactic, and therapeutic efficacy of antibodies in the hyperimmune serum of dromedary in reducing the viral load of MERS CoV, weight loss, and pulmonary pathology in mice.
DIXIT et al., 2016 [84]	Examination of the history of the use of polyclonal antibodies in animals, their developments in safe, and effective products, and the potential application in humans for neglected infectious diseases.
DYALL et al., 2017 [69]	Demonstration of existing therapies in the treatment of coronavirus.
ZHAO et al., 2017 [101]	Demonstration that antibodies from horses immunized with MERS-Cov virus particles are able to neutralize viral infection in mice.
PAN et al., 2020 [102]	Verification of the antigenicity of RBD (receptor binding domain) in mice, production of equine antiserum using RBD as an immunogen, and evaluation of its neutralizing power against SARS-CoV-2.
ZYLBERMAN et al., 2020 [103]	Production of the anti-SARS-CoV-2 serum in Argentina, and its process phases, with the start of a phase 2/3 clinical trial scheduled for July 2020.
SAPKAL et al., 2020 [104]	Development of equine antisera with high neutralizing activity against SARS-CoV-2.
Cunha et al., 2020 [105]	Demonstrated that equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers.
Leon et al., 2020 [106]	Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.